Last updated on April 16, 2014 at 1:21 EDT

Echosens: Launch of the FibroScan®502 Touch

October 27, 2011

PARIS, October 27, 2011 /PRNewswire/ –

Since its initial inception, Echosens has a history of innovation and it
continues to widen and strengthen its product range with the recent
introduction of the FibroScan(R) 502 Touch.

Equipped with a new and more ergonomic tactile interface, and based on
patented Vibration-Controlled Transient Elastography (VCTE(TM)), the latest
FibroScan(R) provides a reliable, accurate and reproducible assessment of
liver tissue stiffness.

This patented VCTE technology, developed by Echosens, is unique in
measuring liver stiffness at a pre-determined and controlled 50 Hz

The FibroScan(R) 502 Touch offers enhanced patient data management with
more complete and personalized exam reports. Compatible with the complete
range of FibroScan probes (S+, M+ and XL+) it offers simultaneous connection
of 2 probes giving flexibility for the patient assessment. An indicator
recommends the probe best suited to the patient’s morphology.

Echosens’ FS 502 Touch represents a quicker and more complete device
built around the latest generation of electronics.

Continuing Echosens’ history of innovation, the FS 502 Touch is further
enhanced by the optional integration of the latest technological innovation:
CAP(TM) (Controlled Attenuation Parameter), the new parameter for steatosis
assessment and quantification.

Echosens has also launched new software for managing FibroScan(R)
examinations: the Desk Solution. This comprehensive and innovative solution
provides ready access to FibroScan assessments on the physician’s desk-top

Echosens products are widely available in most global markets and the
company is actively pursuing the necessary FDA approvals to homologate its
devices for sale in the United States.

About Echosens and Fibroscan(R)

FibroScan(R) is designed to quantify hepatic elasticity and steatosis in
a non-invasive manner in chronic liver diseases assessment.

Founded in 2001, Echosens supplies its products in more than 70
countries through a global network of suppliers. It dedicates a major
portion of its activity to research and development in order to invent new
medical devices and open up new medical perspectives. The organization works
in close cooperation with health professionals and patients’ associations to
facilitate management and therapeutic monitoring of patients. To date, there
around 400 publications which attest to the efficacy of FibroScan in
clinical practice.

        Press Contact

        Richard GUILLAUME

SOURCE Echosens

Source: PR Newswire